Pacira BioSciences (PCRX) Jefferies Global Healthcare Conference 2026 summary

Strategic growth initiatives and market outlook

• Pursuing a 5x30 growth strategy, focusing on expanding product reach and partnerships by 2030.

• Investments in commercial and medical market access have increased payer coverage, with 110 million lives now covered outside the surgical bundle.

• Double-digit growth for EXPAREL is considered possible due to volume acceleration, price increases, and expanded payer access.

• Majority of EXPAREL growth is from deeper penetration in existing accounts and expansion into additional procedures.

• Seasonality affects EXPAREL, with orthopedics as the main business segment, followed by soft tissue, plastics, and dental procedures.

Regulatory and legislative catalysts

• NOPAIN Act is driving growth by enabling reimbursement outside the bundle, with strong early uptake in ambulatory surgery centers.

• Early data show NOPAIN Act is reducing opioid use in hospitals, supporting efforts to renew and expand the legislation beyond 2027.

• Ongoing advocacy aims to extend NOPAIN to inpatient settings and veterans, with continued data sharing with CMS and stakeholders.

Product portfolio performance and partnerships

• EXPAREL revenue guidance for the year is $600–$620 million, with total company revenue guidance at $745–$775 million.

• ZILRETTA grew 15% year-over-year in Q1, aided by a new dedicated sales force and a partnership with Johnson & Johnson MedTech.

• iovera achieved 21% year-over-year growth in Q1, benefiting from a specialized sales team.

• The 5x30 strategy targets five partnerships by 2030, with current collaborations including J&J MedTech (ZILRETTA) and LG Chem (Asia-Pacific).

• Open to further partnerships for all products, including EXPAREL, especially in dental and plastics.